troglitazone has been researched along with Hormone-Dependent Neoplasms in 2 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Colin, C | 1 |
| Salamone, S | 1 |
| Grillier-Vuissoz, I | 1 |
| Boisbrun, M | 1 |
| Kuntz, S | 1 |
| Lecomte, J | 1 |
| Chapleur, Y | 1 |
| Flament, S | 1 |
| Mansour, M | 1 |
| Schwartz, D | 1 |
| Judd, R | 1 |
| Akingbemi, B | 1 |
| Braden, T | 1 |
| Morrison, E | 1 |
| Dennis, J | 1 |
| Bartol, F | 1 |
| Hazi, A | 1 |
| Napier, I | 1 |
| Abdel-Mageed, AB | 1 |
2 other studies available for troglitazone and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
New troglitazone derivatives devoid of PPARĪ³ agonist activity display an increased antiproliferative effect in both hormone-dependent and hormone-independent breast cancer cell lines.
Topics: Antineoplastic Agents; Biotinylation; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell S | 2010 |
Thiazolidinediones/PPARĪ³ agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer.
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Surviv | 2011 |